SARCOMA,SOFT TISSUE
Clinical trials for SARCOMA,SOFT TISSUE explained in plain language.
Never miss a new study
Get alerted when new SARCOMA,SOFT TISSUE trials appear
Sign up with your email to follow new studies for SARCOMA,SOFT TISSUE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Hard-to-Treat sarcomas
Disease control OngoingThis early-phase study tested whether combining the immunotherapy drug pembrolizumab with precise, high-dose radiation (SBRT) is feasible for people with advanced soft-tissue sarcoma that has spread or cannot be removed by surgery. Nine participants received the combination. The …
Matched conditions: SARCOMA,SOFT TISSUE
Phase: EARLY_PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 17, 2026 09:18 UTC
-
New drug combo aims to shrink sarcomas before surgery
Disease control OngoingThis early-phase study tests a drug called ADI-PEG 20 combined with chemotherapy (ifosfamide) and radiation before surgery for soft tissue sarcoma. The goal is to find the safest dose and see if it helps shrink tumors. Only 6 patients with intermediate or high-grade sarcomas of t…
Matched conditions: SARCOMA,SOFT TISSUE
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 17, 2026 09:10 UTC
-
Virus and radiation team up against rare sarcoma
Disease control OngoingThis study tests a new approach for people with advanced soft tissue sarcoma that cannot be easily removed with surgery alone. Participants receive injections of a modified virus (TVEC) directly into the tumor along with standard radiation therapy before surgery. The goal is to s…
Matched conditions: SARCOMA,SOFT TISSUE
Phase: PHASE2 • Sponsor: John Rieth • Aim: Disease control
Last updated May 17, 2026 09:08 UTC
-
New drug duo targets hard-to-treat liposarcoma
Disease control OngoingThis study tests whether combining two drugs (etrumadenant and zimberelimab) can shrink or slow advanced dedifferentiated liposarcoma, a rare soft tissue cancer. About 16 adults whose cancer has returned, spread, or cannot be removed by surgery will receive the treatment. The mai…
Matched conditions: SARCOMA,SOFT TISSUE
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo therapy aims to turn tumors against themselves in advanced cancer patients
Disease control OngoingThis early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…
Matched conditions: SARCOMA,SOFT TISSUE
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New hope for rare sarcomas: targeted pill takes on DNA repair flaws
Disease control OngoingThis study tests a drug called niraparib in people with advanced soft tissue sarcoma that has certain DNA repair mutations. The goal is to see if the drug can shrink tumors or slow their growth. About 8 adults with inoperable or metastatic sarcoma will receive niraparib and be mo…
Matched conditions: SARCOMA,SOFT TISSUE
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 08, 2026 12:03 UTC
-
New drug combo shows promise in fighting rare sarcomas
Disease control OngoingThis study tests whether adding the drug atezolizumab to standard radiotherapy can improve treatment for soft tissue sarcoma. About 62 adults with operable tumors will receive the drug either before or after radiation and surgery. The goal is to see if this approach causes more t…
Matched conditions: SARCOMA,SOFT TISSUE
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated May 06, 2026 16:02 UTC
-
Triple therapy shows promise against rare sarcoma in early trial
Disease control OngoingThis study tests whether combining an immunotherapy drug (pembrolizumab) with another immune-boosting protein (eftilagimod alpha) and radiation therapy can shrink soft tissue sarcomas before surgery. About 40 adults with high-risk, non-spread sarcomas will receive this combinatio…
Matched conditions: SARCOMA,SOFT TISSUE
Phase: PHASE2 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Disease control
Last updated May 05, 2026 11:56 UTC